A new innovation agenda released by the Food and Drug Administration's Center for Veterinary Medicine outlines how CVM plans to address hot-button issues such as approvals for zootechnical feed additives and coordinate on regulating the use of gene editing in animals.
Food and Drug Administration Commissioner Robert Califf said the agency plans to soon announce the naming of the new deputy commissioner of human foods as well as unveil its innovation agenda for the Center for Veterinary Medicine.
Animal industry officials hope the upcoming reauthorization of legislation guiding animal drug reviews will streamline the approval process, preventing the U.S. from falling behind foreign governments.
Tracey Forfa, a 30-year veteran of the Food and Drug Administration,
will become the new director of FDA’s Center for Veterinary Medicine. She has been CVM’s acting director since December, when previous director Steven Solomon retired.
The American Feed Industry Association and National Grain and Feed Association are offering support for a Memorandum of Understanding between feed regulators and the Food and Drug Administration at an FDA listening session.
Stakeholders offered a tepid response to Food and Drug Administration Commissioner Robert Califf’s unveiling Tuesday of a new Humans Foods Program, which Califf said he believes will fundamentally transform the way FDA oversees the U.S. food supply.
Food and Drug Administration Commissioner Robert Califf has proposed creating a new Human Foods Program at the agency and has begun a national search for a newly created deputy commissioner for human foods who would report directly to him.
The Food and Drug Administration will use an outside evaluation released Tuesday to help reform its human foods program, FDA Commissioner Robert Califf said following release of the report by the Reagan-Udall Foundation.
Is a seaweed feed additive which can significantly reduce methane emissions considered a feed ingredient or animal drug? What about an animal food ingredient which could actually reduce the risk of salmonella? According to current Food and Drug Administration policy, the answer is an animal drug, adding years and additional cost to gain approval from FDA.